1. Home
  2. EAF vs PRTC Comparison

EAF vs PRTC Comparison

Compare EAF & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrafTech International Ltd.

EAF

GrafTech International Ltd.

HOLD

Current Price

$15.93

Market Cap

332.0M

Sector

Energy

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.99

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAF
PRTC
Founded
1886
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
332.0M
386.7M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
EAF
PRTC
Price
$15.93
$16.99
Analyst Decision
Hold
Analyst Count
4
0
Target Price
$14.25
N/A
AVG Volume (30 Days)
184.7K
2.1K
Earning Date
02-06-2026
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
$521,894,000.00
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$11.64
N/A
P/E Ratio
N/A
$8.13
Revenue Growth
N/A
1265.60
52 Week Low
$5.50
$13.30
52 Week High
$20.32
$20.00

Technical Indicators

Market Signals
Indicator
EAF
PRTC
Relative Strength Index (RSI) 54.42 51.74
Support Level $13.91 $16.72
Resistance Level $17.09 $17.85
Average True Range (ATR) 1.09 0.42
MACD -0.05 0.04
Stochastic Oscillator 51.94 48.04

Price Performance

Historical Comparison
EAF
PRTC

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: